Harmin

Harmin is a beta-carboline alkaloid found in Peganum harmala and ayahuasca plants that reversibly inhibits monoamine oxidase A (MAO-A). This compound demonstrates neuroprotective and antimicrobial properties in preclinical studies, though human clinical data remains limited.

Origin & History

Harmine is a beta-carboline alkaloid found primarily in plants of the Peganum genus, such as Peganum harmala. It is extracted from plant seeds using chemical processes involving solvents or acid-base methods.

Historical & Cultural Context

Harmine is a primary bioactive alkaloid in Peganum harmala, used historically in traditional medicine systems of the Middle East, North Africa, and Central Asia. Specific traditional indications or durations are not detailed in the sources.

Health Benefits

• Neuroprotective effects, as suggested by preclinical studies in plant extracts containing harmine, though lacking human data.
• Anticancer properties indicated in plant extracts, but with no human trials to support these findings.
• Antimicrobial action noted in preclinical studies, yet human evidence is absent.
• Antiviral potential observed in plant extracts, though no clinical trials confirm these effects in humans.
• Inhibition of monoamine oxidase, which plays a role in neurotransmitter metabolism, as suggested by harmine's mechanism of action.

How It Works

Harmin reversibly inhibits monoamine oxidase A (MAO-A) with an IC50 of approximately 5-10 μM, increasing levels of serotonin, dopamine, and norepinephrine. It also modulates GABA signaling pathways and exhibits antioxidant activity by scavenging free radicals. Additionally, harmin interferes with DNA topoisomerase II activity, contributing to its potential anticancer effects.

Scientific Research

No human clinical trials or meta-analyses have been identified specifically for harmine. Preclinical studies suggest various health effects, but these lack human data and do not provide specific PMIDs.

Clinical Summary

Current evidence for harmin comes primarily from in vitro and animal studies, with no dedicated human clinical trials. Preclinical research shows neuroprotective effects in models of Alzheimer's disease and Parkinson's disease at doses of 10-50 mg/kg in rodents. Antimicrobial studies demonstrate activity against various bacteria and fungi at concentrations of 25-100 μg/mL. The lack of human trials significantly limits conclusions about therapeutic efficacy and optimal dosing in humans.

Nutritional Profile

Harmine (C13H12N2O) is a beta-carboline alkaloid with a molecular weight of 212.25 g/mol. It is not a nutritional ingredient in the conventional sense and contains no macronutrients (0g protein, 0g fat, 0g carbohydrates), no dietary fiber, no vitamins, and no minerals in its isolated compound form. As a pure alkaloid, its profile is defined entirely by its bioactive chemistry: it functions as a reversible inhibitor of monoamine oxidase A (MAO-A) with an IC50 of approximately 5-10 nM in vitro. Harmine is naturally occurring in Peganum harmala seeds (2-7% dry weight), Banisteriopsis caapi vine (0.31-8.43 mg/g dry weight), and Passiflora incarnata aerial parts (trace amounts, approximately 0.0018% dry weight). In isolated form, typical experimental doses referenced in preclinical studies range from 1-20 mg/kg in animal models. Bioavailability data in humans is limited, but harmine is lipophilic (logP approximately 1.35), facilitating passive membrane diffusion and suggesting reasonable oral absorption; it readily crosses the blood-brain barrier due to its lipophilic nature and small molecular size. It undergoes hepatic first-pass metabolism, primarily via CYP1A2-mediated O-demethylation to harmol, which is subsequently conjugated as glucuronide and sulfate metabolites for urinary excretion. No established dietary reference intake or safe upper limit exists for isolated harmine.

Preparation & Dosage

No clinically studied dosage ranges for harmine in extract, powder, or standardized forms are available due to the absence of human trials. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Harmaline, Harmalol, Harmol, Vasicine, Vasicinone

Safety & Interactions

Harmin can cause dangerous interactions with SSRIs, SNRIs, and other antidepressants due to its MAO-A inhibition, potentially leading to serotonin syndrome. Common side effects may include nausea, dizziness, and cardiovascular changes. It should be avoided during pregnancy and breastfeeding due to insufficient safety data. Individuals taking any psychiatric medications or those with cardiovascular conditions should consult healthcare providers before use.